Phase III meta-analysis of first-line chemo-immunotherapy in ES-SCLC: Survival benefit without detectable class-level...

Area of Science:

• Oncology
• Immunotherapy
• Clinical Trials

Background:

• Standard first-line therapy for extensive-stage small-cell lung cancer (ES-SCLC) involves PD-1/PD-L1 inhibitors combined with platinum-etoposide.
• Debate exists regarding the consistency of benefit and potential differences between PD-1 and PD-L1 inhibitor classes in ES-SCLC treatment.

Purpose of the Study:

• To conduct an updated systematic review and meta-analysis of phase III trials in untreated ES-SCLC.
• To evaluate the efficacy and safety of adding PD-1/PD-L1 inhibitors to chemotherapy for ES-SCLC.
• To compare the effects of PD-1 versus PD-L1 inhibitors within this therapeutic context.

Main Methods:

• Systematic search of MEDLINE, Scopus, and Cochrane CENTRAL for relevant phase III randomized trials.
• Pooled hazard ratios (HRs) for overall survival (OS) and progression-free survival (PFS) using random-effects models.
• Meta-regression to assess PD-1 versus PD-L1 class effects and synthesis of safety endpoints using risk ratios (RRs).

Main Results:

• Six trials (n=2,897) demonstrated that chemo-immunotherapy significantly improved OS (HR 0.74) and PFS (HR 0.68).
• No statistically significant difference was detected between PD-1 and PD-L1 inhibitor classes for OS or PFS.
• While Grade ≥3 treatment-related adverse events were not increased, immune-mediated adverse events were more frequent (RR 2.39).

Conclusions:

• Adding a PD-1/PD-L1 inhibitor to platinum-etoposide offers a consistent overall survival benefit for first-line ES-SCLC treatment.
• There are no statistically detectable differences between PD-1 and PD-L1 inhibitor classes in terms of survival benefit.
• The observed lack of class-level divergence suggests absence of detectable differences, not necessarily pharmacologic equivalence.